Trial · NCT02436668
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Ibrutinib+Gemcitabine+Nab-paclitaxel | 5.32 | 95% Confidence Interval 3.75 to 5.49 | Months | |
| Progression Free Survival (PFS) | Placebo+Gemcitabine+Nab-Paclitaxel | 6.01 | 95% Confidence Interval 5.45 to 7.16 | Months | |
| Overall Survival (OS) | Ibrutinib+Gemcitabine+Nab-paclitaxel | 9.69 | 95% Confidence Interval 8.57 to 10.41 | Months | |
| Overall Survival (OS) | Placebo+Gemcitabine+Nab-Paclitaxel | 10.78 | 95% Confidence Interval 8.94 to 11.66 | Months | |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine. | Placebo+Gemcitabine+Nab-Paclitaxel | Subjects with any TEAE >= Grade 3 | 86.8 | percentage of participants | |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine. | Ibrutinib+Gemcitabine+Nab-paclitaxel | Subjects with any TEAE >= Grade 3 | 85.6 | percentage of participants | |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine. | Placebo+Gemcitabine+Nab-Paclitaxel | Subjects with ibrutinib/pbo-related TEAE >=Grade 3 | 55.7 | percentage of participants | |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine. | Ibrutinib+Gemcitabine+Nab-paclitaxel | Subjects with ibrutinib/pbo-related TEAE >=Grade 3 | 54.3 | percentage of participants | |
| Overall Response Rate | Placebo+Gemcitabine+Nab-Paclitaxel | 42.3 | 95% Confidence Interval 35.5 to 49.2 | percentage of Patients | |
| Overall Response Rate | Ibrutinib+Gemcitabine+Nab-paclitaxel | 29.5 | 95% Confidence Interval 23.3 to 36 | percentage of Patients | |
| Clinical Benefit Response | Placebo+Gemcitabine+Nab-Paclitaxel | Achieved a >=50% reduction in pain intensity | 25.8 | percentage of patients | |
| Clinical Benefit Response | Ibrutinib+Gemcitabine+Nab-paclitaxel | Achieved a >=50% reduction in pain intensity | 27.5 | percentage of patients | |
| Clinical Benefit Response | Placebo+Gemcitabine+Nab-Paclitaxel | >=20-pt improvement in KPS (>=4 consecutive weeks) | 1.4 | percentage of patients | |
| Clinical Benefit Response | Ibrutinib+Gemcitabine+Nab-paclitaxel | >=20-pt improvement in KPS (>=4 consecutive weeks) | 0 | percentage of patients | |
| Clinical Benefit Response | Placebo+Gemcitabine+Nab-Paclitaxel | Sustained weight gain (>=7% maintained >4 weeks | 11.7 | percentage of patients | |
| Clinical Benefit Response | Ibrutinib+Gemcitabine+Nab-paclitaxel | Sustained weight gain (>=7% maintained >4 weeks | 5.7 | percentage of patients | |
| Carbohydrate Antigen 19-9 (CA19-9) Response | Placebo+Gemcitabine+Nab-Paclitaxel | 62.9 | 95% Confidence Interval 56.0 to 69.4 | percentage of patients | |
| Carbohydrate Antigen 19-9 (CA19-9) Response | Ibrutinib+Gemcitabine+Nab-paclitaxel | 53.6 | 95% Confidence Interval 46.6 to 60.4 | percentage of patients | |
| Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30). | Placebo+Gemcitabine+Nab-Paclitaxel | 6.14 | 95% Confidence Interval 4.86 to 8.21 | months | |
| Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30). | Ibrutinib+Gemcitabine+Nab-paclitaxel | 4.21 | 95% Confidence Interval 2.86 to 5.82 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02436668/results